Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06455293
PHASE2
Psilocybin Therapy for Depression in Parkinson's Disease
Sponsor: Joshua Woolley, MD, PhD
View on ClinicalTrials.gov
Summary
The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
Official title: The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
Key Details
Gender
All
Age Range
40 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2024-08-19
Completion Date
2028-06
Last Updated
2025-05-13
Healthy Volunteers
No
Conditions
Interventions
DRUG
Psilocybin
Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring
Locations (1)
University of California, San Francisco
San Francisco, California, United States